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claim. Patients were then followed for 30 and 60 days
post initiation of COX-2 therapy to evaluate rate of 
concurrent PPI use.
RESULTS: During 2000, 19,318 COX-2 users were iden-
tiﬁed (1.0% of total membership). Average (median)
number of COX-2 prescriptions ﬁlled was 3.4 (2) pre-
scriptions per COX-2 patient per year (pppy). Average
(median) quantity consumed pppy was 151 (80) capsules
for celecoxib and 91 (60) tablets for rofecoxib. Average
(median) length of therapy was 148 (86) days pppy.
During the study period, 16.7% of patients switched from
celecoxib to rofecoxib and 11.9% switched from rofe-
coxib to celecoxib. Of the 966 previous PPI users identi-
ﬁed, 62.3% and 56.8% continued on PPI therapy at 
30 and 60 days, respectively, post initiation of COX-2
therapy.
CONCLUSIONS: Length of COX-2 therapy for this pop-
ulation was relatively short and the majority of patients
who were utilizing a PPI prior to a COX-2 inhibitor con-
tinued on PPI therapy.
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Evidence for the efﬁcacy of antiresorptive therapies
(ART) is convincing for the most part in terms of risk
reduction of osteoporotic fractures among high-risk
postmenopausal women. Very little information has been
published on the frequency of use of ART.
OBJECTIVE: To evaluate the probability (P) over time of
ART use in women aged 70 years and older who had 
at least one diagnosed osteoporotic fracture to those
without a fracture.
METHODS: A cohort design was used, and a random
sample of women was collected from RAMQ database.
Women were classiﬁed in four cohorts, of which two
status were deﬁned: those with a fracture and those
without fracture in the 5 years prior to cohort entry. The
cohort entry was deﬁned as January 95, 96, 98 and 2000.
These women were followed up for a year after cohort
entry. Several exclusion criteria applied in the 5 years
prior cohort entry were used. We stopped to follow
women at their 85th birth date. The P of ﬁlling at least
one prescription of ART during the year following cohort
entry was determined using a logistic regression adjusting
for age.
RESULTS: Mean age and CDS were 78 years old and 3.3.
Prior use of ART ranged from 8.9% to 31.2%, and 8.7%
to 17.2 for women with and without fracture, respec-
tively. The P of ﬁlling at least one prescription of ART
excluding HRT from 1995 to 2001 ranged from 1.6% to
28.3% and from 0.5% to 11.3% among women with and
without fracture, respectively. The P of ﬁlling at least one
prescription of HRT ranged from 7.2% to 9.3% for
women with and without fracture.
CONCLUSION: Our results show an increase of ART
use excluding HRT overtime. But, there is still an under-
use of ART among women with fracture.
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OBJECTIVE: An estimated 9.4 million people in the
United States have osteoporosis. The prevalence of verte-
bral fractures is estimated at between 10% and 25% in
women aged 50 and over, with recent longitudinal studies
stating that bone loss accelerates with age. The risk for a
fracture is highly predictable by an initial fracture (OR =
2.1), leading to great opportunity for prevention of 
secondary fracture with pharmacotherapy. The purpose
of this study is to assess the prevalence of failing to treat
women, post-fracture, with pharmaceuticals.
METHODS: This is a retrospective database review of 
a Southeastern Michigan managed care organization’s
medical claims data from January 1, 1996, and pharmacy
claims data from January 1, 1997, through March 21,
2001. Data include women > 45 years of age before
January 1, 2001, with diagnosis of non-traumatic frac-
ture via CPT and ICD-9 codes. Treatment is deﬁned with
pharmacy claims data of estrogens, bisphosphonates,
raloxifene, or salmon calcitonin.
RESULTS: We identiﬁed 188 women (mean age at event
= 68.0 years) with fracture eligible for treatment, 89
(47%) did not receive treatment before fracture, and 74
(39%) following fracture. The decrease from 89 patients
pre-fracture to 74 patients post-fracture failing to receive
treatment is the net effect of 6 patients stopping treatment
and 21 patients beginning treatment.
CONCLUSIONS: The occurrence of a fracture represents
an opportunity to prevent further osteoporotic fractures.
There is an opportunity to increase patient outcomes to
prevent secondary fracture in women 45 years and older.
More than one-third of potentially eligible women were
not being treated with available medications.
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OBJECTIVE: The US national cost of osteoporosis was
estimated at $6.1 billion in 1984 and $20 billion in 1998.
